이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hanmi Pharm 미래 성장

Future 기준 확인 1/6

Hanmi Pharm (는) 각각 연간 11.8% 및 5.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.7% 로 예상됩니다.

주요 정보

11.9%

수익 성장률

11.1%

EPS 성장률

Pharmaceuticals 수익 성장	36.1%
매출 성장률	5.5%
향후 자기자본 수익률	15.7%
애널리스트 커버리지	Good
마지막 업데이트	18 Jun 2024

최근 미래 성장 업데이트

Recent updates

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

수익 및 매출 성장 예측

KOSE:A128940 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	1,763,048	224,380	215,967	279,127	13
12/31/2025	1,767,565	190,302	210,023	258,350	19
12/31/2024	1,636,250	178,318	199,292	236,993	18
3/31/2024	1,533,383	158,086	215,064	266,810	N/A
12/31/2023	1,490,887	146,231	173,029	216,538	N/A
9/30/2023	1,419,708	131,316	93,449	133,068	N/A
6/30/2023	1,397,244	101,982	98,900	139,958	N/A
3/31/2023	1,371,607	106,424	100,087	142,458	N/A
12/31/2022	1,331,547	82,792	111,618	162,269	N/A
9/30/2022	1,330,854	80,780	212,242	258,668	N/A
6/30/2022	1,291,788	78,807	222,898	267,987	N/A
3/31/2022	1,253,997	67,497	242,072	281,103	N/A
12/31/2021	1,203,186	67,025	167,776	201,923	N/A
9/30/2021	1,130,015	77,337	186,309	227,481	N/A
6/30/2021	1,093,865	23,092	145,080	185,482	N/A
3/31/2021	1,057,969	23,462	92,160	139,157	N/A
12/31/2020	1,075,854	11,959	93,785	151,535	N/A
9/30/2020	1,101,450	-1,238	27,417	114,463	N/A
6/30/2020	1,100,225	36,049	-15,536	121,852	N/A
3/31/2020	1,127,208	46,907	-118,323	64,277	N/A
12/31/2019	1,113,650	52,110	-165,540	12,447	N/A
9/30/2019	1,104,465	29,815	-151,837	52,148	N/A
6/30/2019	1,074,014	34,892	-178,529	11,181	N/A
3/31/2019	1,044,929	29,971	-167,121	54,106	N/A
12/31/2018	1,015,962	24,891	-184,829	25,982	N/A
9/30/2018	954,879	41,003	-253,511	-57,022	N/A
6/30/2018	947,203	50,120	-286,240	-61,733	N/A
3/31/2018	928,713	49,170	-250,109	-58,807	N/A
12/31/2017	916,586	60,434	N/A	-62,905	N/A
9/30/2017	856,033	12,415	N/A	-499	N/A
6/30/2017	848,177	-3,433	N/A	8,921	N/A
3/31/2017	859,901	4,177	N/A	3,461	N/A
12/31/2016	882,725	23,326	N/A	412,965	N/A
9/30/2016	1,300,579	220,192	N/A	473,881	N/A
6/30/2016	1,349,235	188,682	N/A	439,648	N/A
3/31/2016	1,359,164	179,858	N/A	464,276	N/A
12/31/2015	1,317,535	154,443	N/A	101,712	N/A
9/30/2015	939,070	9,750	N/A	-35,497	N/A
6/30/2015	850,027	37,587	N/A	1,946	N/A
3/31/2015	791,905	33,760	N/A	-35,048	N/A
12/31/2014	761,280	35,510	N/A	-32,820	N/A
9/30/2014	743,779	32,302	N/A	-9,178	N/A
6/30/2014	750,634	45,249	N/A	16,754	N/A
3/31/2014	743,951	45,870	N/A	56,428	N/A
12/31/2013	730,134	43,933	N/A	85,992	N/A
9/30/2013	709,814	45,427	N/A	92,522	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A128940 의 연간 예상 수익 증가율( 11.8% )이 saving rate( 2.5% 보다 높습니다. ).

수익 vs 시장: A128940 의 연간 수익( 11.8% ) KR 시장( 28.8% 보다 느리게 성장할 것으로 예상됩니다. 28.8% 연간).

고성장 수익: A128940 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: A128940 의 수익(연간 5.5% ) KR 시장( 10.5% 보다 느리게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: A128940 의 수익(연간 5.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A128940 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15.7 %).

Hanmi Pharm 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 24%

Consensus EPS estimates increase by 13%

Consensus forecasts updated

Recent updates

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견